Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...

Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Fmr LLC lifted its holdings in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 0.2% during the 3rd quarter, according ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

On Monday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.59 which represents a decrease of $-0.19 or -2.80% from the prior close of $6.78. The stock opened at $6.75 and touched a low ...

On Monday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.66 which represents a decrease of $-0.14 or -2.06% from the prior close of $6.8. The stock opened at $6.81 and touched a low ...